New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 547-559

  Sosnik, Alejandro ^a   Carcaboso, Ángel M ^a   Glisoni, Romina J ^a   Moretton, Marcela A ^a   Chiappetta, Diego A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Complexation; Local delivery to the lung; Pharmaceutical nanotechnology; Polymeric and non polymeric nanoparticles; Polymeric micelles and liposomes; Targeting to alveolar macrophages; Tuberculosis

Indexed keywords

ALVEOLAR MACROPHAGES; LOCAL DELIVERY; LOCAL DELIVERY TO THE LUNG; NON-POLYMERIC; POLYMERIC MICELLE; POLYMERIC MICELLES AND LIPOSOMES; TUBERCULOSIS;

ANTIBIOTICS; BIOLOGICAL ORGANS; COMPLEXATION; CONTROLLED DRUG DELIVERY; CURRICULA; DRUG INTERACTIONS; LIPOSOMES; MACROPHAGES; MICELLES; NANOPARTICLES; NANOTECHNOLOGY; PEDIATRICS; PHOSPHOLIPIDS; TERBIUM ALLOYS;

DRUG THERAPY;

2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ABRIFARM; ACTIMAX; AETINA; AMIKACIN; AMINOSALICYLIC ACID; CAPASTAT SULPHATE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLATHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DENDRIMER; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LIPOSOME; LL 3858; LUKADIN; MIKAVIR; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NANOCARRIER; NANOPARTICLE; NIOSOME; NOVAMIN; PASER; POLYMER; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPRODIN; SESQUISULFATE AGRISTREP; STREPTOBRETTIN; STREPTOMYCIN; SUDOTERB; SULFATE AMIGLYDE V; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; ENCAPSULATION; GLYCOSYLATION; HUMAN; HYDRATION; MICELLE; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; THERMODYNAMICS; TREATMENT DURATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DENDRIMERS; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; TUBERCULOSIS;

EID: 76849093957     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.023     Document Type: Review

References (130)

1. Kaufmann S.H., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 11 (2005) S33-S44
2. Gaspar M.M., Cruz A., Fraga A.G., Castro A.G., Cruz M.E.M., and Pedrosa J. Developments on drug delivery systems for the treatment of mycobacterial infections. Curr. Top. Med. Chem. 8 (2008) 579-591
3. Tuberculosis. The International Union Against Tuberculosis and Lung Disease (The Union). http://www.theunion.org/tuberculosis/tuberculosis.html (accessed February 2008).
4. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Tuberculosis (Seminar). Lancet 362 (2003) 887-899
5. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf (accessed February 2008).
6. du Toit L.C., Pillay V., and Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. 7 (2006) 1-18
7. Jain S.K., Lamichhane G., Nimmagadda S., Pomper M.G., and Bishai W.R. Antibiotic treatment of tuberculosis: old problems, new solutions. Microbe 3 (2008) 285-292
8. WHO. World Health Organization declares tuberculosis a global emergency. Soc. Prevent. Med. 38 (1993) 251-252
9. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16 (2003) 463-496
10. Schluger N.W. The pathogenesis of tuberculosis. The first one hundred (and twenty-three) years. Am. J. Respir. Cell Mol. Biol. 32 (2005) 251-256
11. Onyebujoh P., Zumla A., Ribeiro I., Rustomjee R., Mwaba P., Gomes M., and Grange J.M. Treatment of tuberculosis: present status and future prospects. Bull. World Health Organ. 83 (2005) 857-865
12. WHO. Treatment of tuberculosis: guidelines for national programmes. 3rd Geneva World Health Organization (2003)
13. Rook G.A.W., and Hernandez-Pando R. The pathogenesis of tuberculosis. Annu. Rev. Microbiol. 50 (1996) 259-284
14. Dye C. Global epidemiology of tuberculosis. Lancet 367 (2006) 938-940
15. Gupta R., Kim J.Y., Espinal M.A., Caudron J.-M., Pecoul B., Farmer P.E., and Raviglione M.C. Responding to market failures in tuberculosis control. Science 293 (2001) 1049-1051
16. Ellard G.A., and Fourie P.B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int. J. Tuberc. Lung Dis. 3 (1999) S301-S308
17. Blomberg B., Spinaci S., Fourie B., and Laing R. The rationale for recommending fixed dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 79 (2001) 61-68
18. Yager P., Domingo G.J., and Gerdes J. Point-of-care diagnostics for global health. Annu. Rev. Biomed. Eng. 10 (2008) 107-144
19. Mitnick C.D., Appleton S.C., and Shin S.S. Epidemiology and treatment of multidrug resistant tuberculosis. Semin. Respir. Crit. Care Med. 29 (2008) 499-524
20. Mukherjee J.S., Rich M.L., Socci A.R., Joseph J.K., Viru F.A., Shin S.S., Furin J.J., Becerra M.C., Barry D.J., Kim J.Y., Bayona J., Farmer P., Smith Fawzi M.C., and Seung K.J. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363 (2004) 474-481
21. Sahai J., Gallicano K., Swick L., Tailor S., Garber G., Seguin I., Oliveras L., Walker S., Rachlis A., and William Cameron D. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127 (1997) 289-293
22. Pinheiro V.G.F., Ramos L.M.A., Monteiro H.S.A., Barroso E.C., Bushen O.Y., Façanha M.C., Peloquin C.A., Guerrant R.L., and Lima A.A.M. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz. J. Infect. Dis. 10 (2006) 374-379
23. Gohel M.C., and Sarvaiya K.G. A novel solid dosage form of rifampicin and isoniazid with improved functionality. AAPS PharmSciTech 8 (2007) Article 68
24. Prankerd R.J., Walters J.M., and Pames J.H. Kinetics for degradation of rifampicin and azomethine-containing drug which exhibits reversible hydrolysis in acidic solutions. Int. J. Pharm. 78 (1992) 59-67
25. Mariappan T.T., and Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int. J. Tuberc. Lung Dis. 7 (2003) 797-803
26. Mariappan T.T., and Singh S. Positioning of rifampicin in the Biopharmaceutics Classification System (BCS). Clin. Res. Regul. Aff. 23 (2006) 1-10
27. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
28. Maggi N., Vigevani A., Gallo G.G., and Pasqualucci C.R. Acetyl migration in rifampicin. J. Med. Chem. 11 (1968) 936-939
29. Shishoo C.J., Shah S.A., Rathod I.S., Savale S.S., Kotecha J.S., and Shah P.B. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 190 (1999) 109-123
30. Singh S., Mariappan T.T., Sharda N., Kumar S., and Chakrabarti A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 6 (2000) 405-410
31. Tuberculosis. fact sheets. TB and children, http://www.searo.who.int/en/Section10/Section2097/Section2106_10681.htm (accessed February 2008).
32. Koup J.R., Williams-Warren J., Viswanathan C.T., Weber A., and Smith A.L. Pharmacokinetics of rifampin in children II. Oral bioavailability. Ther. Drug Monit. 8 (1986) 17-22
33. Smith K.C., and Seaworth B.J. Drug-resistant tuberculosis: controversies and challenges in pediatrics. Expert Rev. Anti Infect. Ther. 3 (2005) 995-1010
34. Hill S., Regondi I., Grzemska M., and Matirua R. Children and tuberculosis medicines: bridging the research gap. Bull. World Health Organ. 86 (2008) 9
35. Guy E.S., and Mallampalli A. Managing TB in the 21st century: existing and novel drug therapies. Ther. Adv. Respir. Dis. 2 (2008) 401-408
36. New TB drugs under clinical trial, TB Alliance, press release (November 11th 2007) www.tballiance.org.
37. Rivers E.C., and Mancera R.L. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today 13 (2008) 1090-1098
38. Devalapally H., Chakilam A., and Amiji M.M. Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci. 96 (2007) 2547-2555
39. Gelperina S., Kisich K., Iseman M.D., and Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172 (2005) 1487-1490
40. Pison U., Welte T., Giersig M., and Groneberg D.A. Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 533 (2006) 341-350
41. The Nanoparticle Drug Delivery Market, http://www.cientifica.com (accessed February 2008).
42. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
43. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Müller R.H., and Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45 (2000) 77-83
44. Reverchon E., De Marco I., and Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation. Int. J. Pharm. 243 (2002) 83-91
45. Reverchon E., and Della Porta G. Micronization of antibiotics by supercritical assisted atomization. J. Supercrit. Fluids 26 (2003) 243-252
46. Williart J.F., and Descamps M. Solid state amorphization of pharmaceuticals. Mol. Pharmacol. 5 (2008) 905-920
47. Kesisoglou F., Panmai S., and Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59 (2007) 631-644
48. Constantinides P.P., Chaubal M.V., and Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60 (2008) 757-767
49. ®), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm. 273 (2004) 75-83
50. Singh K.K., and Vingkar S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm. 347 (2008) 136-143
51. Ahmed M., Ramadan W., Rambhu D., and Shakeel F. Potential of nanoemulsions for intravenous delivery of rifampicin. Pharmazie 63 (2008) 806-811
52. Sahin N.O. Niosomes as nanocarrier systems. In: Mozafari M.R. (Ed). Nanomaterials and Nanosystems for Biomedical Applications (2007), Springer, Netherlands 67-81
53. Jain C.P., and Vyas S.P. Preparation and characterization of niosomes containing rifampicin for lung targeting. J. Microencapsul 12 (1995) 401-407
54. Jain C.P., Vyas S.P., and Dixit V.K. Niosomal system for delivery of rifampicin to lymphatics. Indian J. Pharm. Sci. 68 (2006) 575-578
55. Mullaicharam A.R., and Murthy R.S.R. Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat. J. Drug Deliv. Sci. Technol. 14 (2004) 99-104
56. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 (2001) 1-20
57. Delie F., and Blanco-Prieto M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10 (2005) 65-80
58. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116 (1995) 1-9
59. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
60. Anisimova Y.V., Gelperina S.I., Peloquin C.A., and Heifets L.B. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2 (2000) 165-171
61. Kisich K.O., Gelperina S.I., Higgins M.P., Wilson S., Shipulo E., Oganesyan E., and Heifets L.B. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm. 345 (2007) 154-162
62. Shipulo E.V., Lyubimov I.I., Maksimenko O.O., Vanchugova L.V., Oganesyan E.A., Sveshnikov P.G., Biketov S.F., Severin E.S., Heifets L.B., and Gelperina S.E. Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate). Pharm. Chem. J. 42 (2008) 145-149
63. Pandey R., Zahoor A., Sharma S., and Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83 (2003) 373-378
64. Pandey R., and Khuller G.K. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J. Antimicrob. Chemother. 57 (2006) 1146-1152
65. Pandey R., and Khuller G.K. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J. Antimicrob. Chemother. 54 (2004) 266-268
66. Zahoor A., Pandey R., Sharma S., and Khuller G.K. Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int. J. Antimicrob. Agents 27 (2006) 409-416
67. Pandey R., Sharma S., and Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 85 (2005) 415-420
68. Sharma A., Sharma S., and Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54 (2004) 761-766
69. du Toit L.C., Pillay V., Choonara Y.E., and Iyuke S.E. Formulation and evaluation of a salted-out isoniazid-loaded nanosystem. AAPS PharmSciTech 9 (2008) 174-181
70. Kataoka K., Harada A., and Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47 (2001) 113-131
71. Croy S.R., and Kwon G.S. Polymeric micelles for drug delivery. Curr. Pharm. Des. 12 (2006) 4669-4684
72. Moghimi S.M., Muir I.S., Illum L., Davis S.S., and Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179 (1993) 157-165
73. Chiappetta D.A., and Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66 (2007) 303-317
74. M.A. Moretton, R.J. Glisoni, D.A. Chiappetta, A. Sosnik, Synthesis and characterization of amphiphilic poly/epsilon-caprolactone)-poly(ethyleneglycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles, BIOOMAT 2009, I Workshop on Artificial Organs, Biomaterials and Tissue Engineering, Latin American Society of Biomaterials, Tissue Engineering and Artificial Organs (SLABO), Rosario, Argentina, August 2009.
75. Jiang Z., You Y., Deng X., and Hao J. Injectable hydrogels of poly(ε-caprolactone-co-glycolide)-poly(ethylene glycol)-poly(ε-caprolactone-co glycolide) triblock copolymer aqueous solutions. Polymer 48 (2007) 4786-4792
76. Chen L., Xie Z., Hu J., Chen X., and Jing X. Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery. J. Nanopart. Res. 9 (2007) 777-785
77. Wu Y., Li M., and Gao H. Polymeric micelle composed of PLA and chitosan as a drug carrier. J. Polym. Res. 16 (2009) 11-18
78. Silva M., Lara A.S., Leite C.Q.F., and Ferreira E.I. Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid. Arch. Pharm. Pharm. Med. Chem. 334 (2001) 189-193
79. Silva M., Ricelli N.L., El Seoud O., Valentim C.S., Ferreira A.G., Sato D.N., Leite C.Q.F., and Ferreira E.I. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug. Arch. Pharm. Chem. Life Sci. 339 (2006) 283-290
80. Silva M., Ferreira E.I., Leite C.Q.F., and Sato D.N. Preparation of polymeric micelles for use as carriers of tuberculostatic drugs. Trop. J. Pharm. Res. 6 (2007) 815-824
81. Jin Y., Chen S., Xin R., and Zhou Y. Monolayers of the lipid derivatives of isoniazid at the air/water interface and the formation of self-assembled nanostructures in water. Colloids Surf., B Biointerfaces 64 (2008) 229-235
82. Tomalia D.A. Birth of new molecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 30 (2005) 294-324
83. D ́Emanuele A., and Attwood D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 57 (2005) 2147-2162
84. Duncan R., and Izzo L. Dendrimers biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57 (2005) 2215-2237
85. Jevprasesphant R., Penny J., Jalal R., Attwood D., McKeown N.B., and D ́Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252 (2003) 263-266
86. P.V. Kumar, A. Asthana, T. Dutta, N.K. Jain, Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers, J. Drug Target. 14 (2006) 546-556.
87. Kumar P.V., Agashe H., Dutta T., and Jain N.K. PEGylated dendritic architecture for development of a prolonged drug delivery system of an antitubercular drug. Curr. Drug Deliv. 4 (2007) 11-19
88. Loftsson T., and Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329 (2007) 1-11
89. Brewster M.E., and Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59 (2007) 645-666
90. Wu A., Shen X., and He Y. Investigation on γ-cyclodextrin nanotube induced by N, N′-diphenylbenzidine molecule. J. Colloid Interface Sci. 297 (2006) 525-533
91. Gonzalez-Gaitano G., Rodriguez P., Isasi J.R., Fuentes M., Tardajos G., and Sanchez M. The aggregation of cyclodextrins as studied by photon correlation spectroscopy. J. Incl. Phenom. Macrocycl. Chem. 44 (2002) 101-105
92. Ferreira D.A., Ferreira A.G., Vizzotto L., Federman Neto A., and Gomes de Oliveira A. Analysis of the molecular association of rifampicin with hydroxypropyl-β-cyclodextrin. Braz. J. Pharm. Sci. 40 (2004) 43-51
93. Mehta S.K., Bhasin K.K., Mehta N., and Dham S. Behavior of rifampicin in association with β-cyclodextrin in aqueous media: a spectroscopic and conductometric study. Colloid Polym. Sci. 283 (2005) 532-538
94. Prakash Rao B., Suresh S., Narendra C., and Balasangameshwer. Physicochemical characterization of β-cyclodextrin and hydroxy ethyl β-cyclodextrin complexes of rifampicina. Ars Pharm. 47 (2006) 37-59
95. Lindenberg M., Kopp S., and Dressman J.B. Classification of orally administered drug on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System. Eur. J. Pharm. Biopharm. 58 (2004) 265-278
96. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Tompkins N.M., Rose J.D., Reynolds R.C., and Orme I.M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49 (2005) 2294-2301
97. Evrard B., Bertholet P., Gueders M., Flament M.P., Piel G., Delattre L., Gayot A., Leterme P., Foidart J.M., and Cataldo D. Cyclodextrins as a potential carrier in drug nebulization. J. Control. Release 96 (2004) 403-410
98. Gregoriadis G., Wills E.J., Swain C.P., and Tavill A.S. Drug carrier potential of liposomes in cancer chemotherapy. Lancet 1 (1974) 1313-1316
99. Klemens S.P., Cynamon M.H., Swenson C.E., and Ginsberg R.S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 34 (1990) 967-970
100. Leitzke S., Bucke W., Borner K., Muller R., Hahn H., and Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob. Agents Chemother. 42 (1998) 459-461
101. Oh Y.K., Nix D.E., and Straubinger R.M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 39 (1995) 2104-2111
102. Duzgunes N., Flasher D., Reddy M.V., Luna-Herrera J., and Gangadharam P.R. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 40 (1996) 2618-2621
103. Deol P., and Khuller G.K. Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochem. Biophys. Acta 1334 (1997) 161-172
104. Deol P., Khuller G.K., and Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41 (1997) 1211-1214
105. Mehta R.T., Keyhani A., McQueen T.J., Rosenbaum B., Rolston K.V., and Tarrand J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37 (1999) 2584-2587
106. Adams L.B., Sinha I., Franzblau S.G., Krahenbuhl J.L., and Mehta R.T. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob. Agents Chemother. 43 (1999) 1638-1643
107. El-Ridy M.S., Mostafa D.M., Shehab A., Nasr E.A., and El-Alim S.A. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int. J. Pharm. 330 (2007) 82-88
108. Gaspar M.M., Cruz A., Penha A.F., Reymao J., Sousa A.C., Eleutério C.V., Domingues S.A., Fraga A.G., Longatto Filho A., Cruz M.E.M., and Pedrosa J. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int. J. Antimicrob. Agents 31 (2008) 37-45
109. Pandey R., and Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55 (2005) 430-435
110. Gill S., Löbenberg R., Ku T., Azarmi S., Roa W., and Prenner E.J. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery-A review. J. Biomed. Nanotechnol. 3 (2007) 107-119
111. Azarmi S., Roa W.H., and Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60 (2008) 863-875
112. Sham J.O., Zhang Y., Finlay W.H., Roa W.H., and Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269 (2004) 457-467
113. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., and Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52 (2003) 981-986
114. Zahoor A., Sharma S., and Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26 (2005) 298-303
115. Ohashi K., Kabasawa T., Ozeki T., and Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135 (2009) 19-24
116. Vyas S.P., Kannan M.E., Jain S., Mishra V., and Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269 (2004) 37-49
117. Matilainen L., Toropainen T., Vihola H., Hirvonen J., Jarvinen T., Jarho P., and Jarvinen K. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J. Control. Release 126 (2008) 10-16
118. Tewes F., Brillault J., Couet W., and Olivier J.-C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control. Release 129 (2008) 93-99
119. Irache J.M., Salman H.H., Gamazo C., and Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5 (2008) 703-724
120. Lane K.B., Egan B., Vick S., Abdolrasulnia R., and Shepherd V.L. Characterization of a rat alveolar macrophage cell line that expresses a functional mannose receptor. J. Leukoc. Biol. 64 (1998) 345-350
121. Chono S., Tanino T., Seki T., and Morimoto K. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J. Pharm. Pharmacol. 59 (2007) 75-80
122. Chono S., Tanino T., Seki T., and Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 127 (2008) 50-58
123. Wijagkanalan W., Kawakami S., Takenaga M., Igarashi R., Yamashita F., and Hashida M. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J. Control. Release 125 (2008) 121-130
124. Vermehren C., Frokjaer S., Aurstad T., and Hansen J. Lung surfactant as a drug delivery system. Int. J. Pharm. 307 (2006) 89-92
125. Poelma D.L., Zimmermann L.J.I., Scholten H.H., Lachmann B., and Iwaarden van J.F. In vivo and in vitro uptake of surfactant lipids by alveolar type II cells and macrophages. Am. J. Physiol., Lung Cell. Mol. Physiol. 283 (2002) L648-L654
126. Benatar S.R., and Fleischer T.E. Ethical issues in research in low-income countries. Int. J. Tuberc. Lung Dis. 11 (2007) 617-623
127. Bhalla A., Suri V., and Malhotra S. Patents on therapeutics in developing countries: the challenges ahead. Expert Opin. Ther. Pat. 17 (2007) 1015-1025
128. Satyanarayana K., and Srivastava S. Poverty, health & intellectual property rights with special reference to India. Indian J. Med. Res. 126 (2007) 390-406
129. The Global Alliance for TB drug development (TB Alliance). http://www.tballiance.org (accessed March 2009).
130. Ito B., and Yamagata T. Who develops innovations in medicine for the poor? Trends in patent applications related to medicines for HIV/AIDS, tuberculosis, malaria and neglected diseases. Dev. Econ. XLV-2 (2007) 141-171